NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).

被引：0
|
作者：
Tan, Antoinette R.
Buyse, Marc E.
Rastogi, Priya
Jacobs, Samuel A.
Robidoux, Andre
Flynn, Patrick J.
Thirlwell, Michael P.
Fehrenbacher, Louis
Stella, Philip J.
Goel, Rakesh
Julian, Thomas B.
Provencher, Louise
Bury, Martin Joseph
Paik, Soonmyung
Geyer, Charles E.
Swain, Sandra M.
Mamounas, Eleftherios P.
Wolmark, Norman
机构：
[1] Natl Surg Adjuvant Breast & Bowel Project, New Brunswick, NJ USA
[2] Canc Inst New Jersey, New Brunswick, NJ USA
[3] Int Inst Drug Dev, Louvain, Belgium
[4] NSABP, Pittsburgh, PA USA
[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[6] NSABP, Montreal, PQ, Canada
[7] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[8] NSABP, St Louis Pk, MN USA
[9] Metro Minnesota Community Clin Oncol Project, St Louis Pk, MN USA
[10] Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada
[11] NSABP, Vallejo, CA USA
[12] Kaiser Permanente Northern Calif, Vallejo, CA USA
[13] NSABP, Ann Arbor, MI USA
[14] St Joseph Mercy Hlth Syst, Ann Arbor, MI USA
[15] NSABP, Ottawa, ON, Canada
[16] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[17] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA
[18] NSABP, Quebec City, PQ, Canada
[19] Ctr Hosp Affilie Univ Quebec, Hop St Sacrement, Quebec City, PQ 75390, Canada
[20] NSABP, Grand Rapids, MI USA
[21] Grand Rapids Clin Oncol Program, Grand Rapids, MI USA
[22] NSABP, Dallas, TX USA
[23] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[24] NSABP, Washington, DC USA
[25] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA
[26] NSABP, Canton, OH USA
[27] Aultman Hosp, Canton, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1025
引用
收藏
页数：1
相关论文
共 50 条
  • [21] An exploratory correlative biomarker analysis of NSABP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N plus T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer
    Gavin, P. G.
    Kim, P. S.
    Lipchick, C.
    Langley, E.
    Feng, H.
    Meyer, G. R.
    Kim, S. Rim
    Michel, J. P.
    Jacobs, S. A.
    Srinivasan, A.
    Pogue-Geile, K. L.
    CANCER RESEARCH, 2017, 77
  • [22] Phase II study of AC (doxorubicin and cyclophosphamide) followed by weekly paclitaxel as neoadjuvant chemotherapy in operable patients with primary breast cancer
    Iwase, S.
    Yamamoto, D.
    Kitamura, K.
    Odagiri, H.
    Teramoto, S.
    Ohtani, S.
    Doi, T.
    Kinebuchi, K.
    Kuroda, Y.
    Nagumo, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Neoadjuvant chemotherapy with gemcitabine(G), epirubicin(E), and paclitaxel(T) in locally advanced breast cancer(LABC): A phase II trial of the NSABP Foundation Research Group.
    Hamm, J
    Wilson, J
    Lembersky, BC
    Robidoux, A
    Raymond, J
    Kardinal, C
    DiNunno, L
    Melemed, A
    Geyer, CE
    Paik, S
    Wolmark, N
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S53 - S53
  • [24] Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide plus /- Trastuzumab Followed by Docetaxel in Locally Advanced Breast Cancer (LABC)
    Tuxen, M. K.
    Cold, S.
    Tange, U. B.
    Soendergaard, S. B.
    Nielsen, D. L.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S173 - S173
  • [25] Phase II trial of neoadjuvant sequential FEC100 followed by docetaxel and capecitabine for HER2-negative locally advanced breast cancer (LABC): A multicenter study from British Columbia
    Chia, S. K.
    Lohrisch, C.
    Gelmon, K.
    Kennecke, H.
    Pansegrau, G.
    Taylor, M.
    Attwell, A.
    Jepson, D.
    Hayes, M.
    Shenkier, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: A phase II trial of the NSABP foundation research group
    Hamm, John T.
    Wilson, John W.
    Rastogi, Priya
    Lembersky, Barry C.
    Tseng, George C.
    Song, Young K.
    Kim, Wanseop
    Robidoux, Andre
    Raymond, Jane M.
    Kardinal, Carl G.
    Shalaby, Ibrahim A.
    Ansari, Rafat
    Paik, Soonmyung
    Geyer, Charles E.
    Wolmark, Norman
    CLINICAL BREAST CANCER, 2008, 8 (03) : 257 - 263
  • [27] Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer
    Mrozek, Ewa
    Layman, Rachel
    Ramaswamy, Bhuvaneswari
    Lustberg, Maryam
    Vecchione, Andrea
    Knopp, Michael V.
    Shapiro, Charles L.
    CLINICAL BREAST CANCER, 2014, 14 (04) : 228 - 234
  • [28] Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer
    Yardley, Denise A.
    Shipley, Dianna L.
    Peacock, Nancy W.
    Shastry, Mythili
    Midha, Rajiv
    Priego, Victor M.
    Hainsworth, John D.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (03) : 557 - 567
  • [29] Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer
    Denise A. Yardley
    Dianna L. Shipley
    Nancy W. Peacock
    Mythili Shastry
    Rajiv Midha
    Victor M. Priego
    John D. Hainsworth
    Breast Cancer Research and Treatment, 2015, 152 : 557 - 567
  • [30] A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC)
    Bedard, P.
    Mates, M.
    Gelmon, K. A.
    Hilton, J.
    Tu, D.
    Li, I.
    Rastgou, L.
    Drummond-Ivars, N.
    Edwards, J.
    Warr, D.
    Lohrisch, C.
    Song, X.
    Srikanthan, A.
    Robinson, A.
    Hagerman, L.
    Seymour, L. K.
    Rushton, M.
    Cescon, D. W.
    ANNALS OF ONCOLOGY, 2020, 31 : S7 - S7
12345